Show simple item record

dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorBairaktari, Eleni Then
dc.contributor.authorKalef-Ezra, J. A.en
dc.contributor.authorNikolaides, C.en
dc.contributor.authorSeferiadis, C.en
dc.contributor.authorFountzilas, Georgeen
dc.creatorPavlidis, Nicholasen
dc.creatorBairaktari, Eleni Then
dc.creatorKalef-Ezra, J. A.en
dc.creatorNikolaides, C.en
dc.creatorSeferiadis, C.en
dc.creatorFountzilas, Georgeen
dc.date.accessioned2018-06-22T09:54:16Z
dc.date.available2018-06-22T09:54:16Z
dc.date.issued1995
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/42271
dc.description.abstractThe levels of soluble interleulkin-2 receptors (sIL-R2) were measured in the serum of 52 patients with epithelial ovarian carcinoma as well as in 25 age and sex-matched normal controls. The mean serum level of sIL-2R was increased in 37 patients (71.2%). Comparison of these levels to those of normal controls showed a highly statistically significant difference (p< 0.001). Serum sIL-2R levels were not related to histology, clinical stage or the presence of ascites (p=0.58, p=0.32 and p=0.67, respectively), nor did they follow disease activity or response to chemotherapy. However patients with higher pretreatment sIL-2R levels (more than 1200 U/ml) were found to have a longer survival (p<0.02), possibly explained by the presence of activated lymphocytes and a better immune surveillance. We conclude that the serum level of sIL-2R: a) is elevated in ovarian cancer patients, b) has no relationship with histological subtypes, tumor burden or the presence of ascites, c) cannot serve as a valuable tumor marker for the monitoring of patient treatment, and d) has a prognostic value for survival.en
dc.language.isoengen
dc.sourceInternational Journal of Biological Markersen
dc.subjectArticleen
dc.subjectHumanen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectControlled studyen
dc.subjectFemaleen
dc.subjectCa-125 antigenen
dc.subjectCancer survivalen
dc.subjectOvarian canceren
dc.subjectOvarian neoplasmsen
dc.subjectRetrospective studiesen
dc.subjectClinical articleen
dc.subjectTreatment outcomeen
dc.subjectPrognosisen
dc.subjectCarcinomaen
dc.subjectInterleukin-2en
dc.subjectReceptorsen
dc.subjectInterleukin 2 receptoren
dc.subjectBiologicalen
dc.subjectTumor markersen
dc.subjectMiddle ageen
dc.subjectNeoplasm proteinsen
dc.subjectOvary carcinomaen
dc.subjectCa 125en
dc.subjectAscitesen
dc.subjectSolubilityen
dc.subjectSoluble interleukin-2 receptorsen
dc.subjectTumor markeren
dc.titleSerum soluble interleukin-2 receptors in epithelial ovarian cancer patientsen
dc.typeinfo:eu-repo/semantics/article
dc.description.volume10
dc.description.issue2
dc.description.startingpage75
dc.description.endingpage80
dc.author.facultyΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record